US4196192A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Combined Haemophilus influenzae type b and pertussis vaccine
Assignee: Wyeth Holdings LLC
•
Filing: 1977-10-28
•
Granted: 1980-04-01
•
Expires: 1997-10-28
Abstract
Abstract A process for the isolation and purification of immunologically active polyribosyl ribitol phosphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b. The PRP has been purified with ethanol, Cetavlon (hexadecyltrimethyl ammonium bromide) and a phosphate containing adsorbent, hydroxylapatite. The contaminants (nucleic acid, proteins and endotoxins) are removed to the minimum level by a treatment with hydroxylapatite. Also described is a process for the preparation of a combined vaccine containing the PRP (prepared as aforementioned) and B. pertussis antigens. The vaccine elicits anti-PRP antibody and antipertussis antibody (as measured by microagglutination) formations in young animals. This sera with anti-PRP antibody exhibits a strong bactericidal activity.
Inventors
- 👤 Joseph S. C. Kuo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K35/00; A61K35/66; A61K35/74; A61K39/00; A61K39/02; A61K39/099; A61K39/102; A61K2039/70; Y; Y10; Y10S; Y10S424/00; Y10S424/831
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
96 words
A combined vaccine that elicits effective levels of anti-PRP (polyribosyl ribitol phosphate) and anti-pertussis antibody formations in young warm-blooded animals which consists of polyribosyl ribitol phosphate isolated and purified from the capsular polysaccharide of Haemophilus influenzae type b by adding hydroxylapatite in about 20 millimolar phosphate buffer at pH from about 6.7 to about 6.9, mixing at a temperature of about 1° to 4° C., centrifuging, and removing the supernatant and repeating the foregoing procedure at least 2 more times, filtering the supernatant, dializing against pyrogen free distilled water, and then lyophilizing; and Bordetella pertussis antigens.
Claim 2
Dependent Claim
96 words
A combined vaccine that elicits effective levels of anti-PRP (polyribosyl ribitol phosphate) and anti-pertussis antibody formations in young warm-blooded animals which consists of polyribosyl ribitol phosphate isolated and purified from the capsular polysaccharide of Haemophilus influenzae type b by adding hydroxylapatite in about 20 millimolar phosphate buffer at pH from about 6.7 to about 6.9, mixing at a temperature of about 1° to 4° C., centrifuging, and removing the supernatant and repeating the foregoing procedure at least 2 more times, filtering the supernatant, dializing against pyrogen free distilled water, and then lyophilizing; and Bordetella pertussis antigens.
Claim 3
Dependent Claim
19 words
A combined vaccine according to claim 1, wherein said Bordetella pertussis antigens are obtained from Bordetella pertussis strain 138.
Claim 4
Dependent Claim
21 words
A combined vaccine according to claim 1, wherein said polyribosyl ribitol phosphate is obtained from Haemophilus influenzae type b Rab strain.
Claim 5
Dependent Claim
33 words
A combined vaccine according to claim 1, wherein said Bordetella pertussis antigens are obtained from Bordetella pertussis strain 138 and said polyribosyl ribitol phosphate is obtained from Haemophilus influenzae type b Rab strain.
Claim 6
Dependent Claim
16 words
A combined vaccine according to claim 1, wherein said young warm-blooded animal is a human child.
Claim 7
Dependent Claim
16 words
A combined vaccine according to claim 4, wherein said young warm-blooded animal is a human child.
Claim 8
Independent Claim
106 words
A method for inducing active immunization against systemic infection in young warm-blooded animals caused by the pathogen Haemophilus influenzae type b which comprises administering an immunogenic amount of a combined vaccine which consists of polyribosyl ribitol phosphate, isolated and purified from the capsular polysaccharide of Haemophilus influenzae type b by adding hydroxylapatite in about 20 millimolar phosphate buffer at pH from about 6.7 to about 6.9, mixing at a temperature of about 1° to 4° C. centrifuging, removing the supernatant and repeating the foregoing procedure at least 2 more times, filtering the supernatant, dializing against pyrogen free distilled water, and then lyophilizing; and Bordetella pertussis antigens.
Claim 9
Independent Claim
106 words
A method for inducing active immunization against systemic infection in young warm-blooded animals caused by the pathogen Haemophilus influenzae type b which comprises administering an immunogenic amount of a combined vaccine which consists of polyribosyl ribitol phosphate, isolated and purified from the capsular polysaccharide of Haemophilus influenzae type b by adding hydroxylapatite in about 20 millimolar phosphate buffer at pH from about 6.7 to about 6.9, mixing at a temperature of about 1° to 4° C. centrifuging, removing the supernatant and repeating the foregoing procedure at least 2 more times, filtering the supernatant, dializing against pyrogen free distilled water, and then lyophilizing; and Bordetella pertussis antigens.
Claim 10
Dependent Claim
12 words
A method according to claim 7, wherein said systemic infection is meningitis.
Claim 11
Dependent Claim
15 words
A method according to claim 8, wherein said young warm-blooded animal is a human child.
References Cited (Backward Citations)
US4029766A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-04-01 | 1983-10-01 | 1984-04-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-04-01 | 1987-10-01 | 1988-04-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-04-01 | 1991-10-01 | 1992-04-01 | $7700.00 | Window Closed / Lapsed |